{"preliminary_commentary":{"by_channel":{"x_thread":4,"youtube":2,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[],"indication":"refractory acute leukemia","name":"AATT","nct_id":"NCT00984412","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=aatt-nct00984412. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"AATT","arms":[{"description":null,"label":"AATT","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2020-11","type":"ESTIMATED"},"conditions":["Refractory Acute Leukemia"],"enrollment":{"count":15,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Allogeneic hematopoietic stem-cell-transplantation","otherNames":[],"type":"PROCEDURE"}],"last_update":"2016-02-19","lead_sponsor":"Hadassah Medical Organization","official_title":"Allo-allo Tandem Matched Stem Cell Transplantation (AATT) for the Treatment of Patients With Refractory Acute Leukemia; a Feasibility Phase I/II Study","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2020-04","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Transplant-related mortality (TRM) of SCT II.","timeFrame":"240d"},{"measure":"Transplant-related toxicity (TRT) of SCT II.","timeFrame":"240d"}],"references":[{"citation":"Tournilhac O, Altmann B, Friedrichs B, Bouabdallah K, Leclerc M, Cartron G, Turlure P, Reimer P, Wagner-Drouet E, Sanhes L, Houot R, Roussel M, Kroschinsky F, Dreger P, Viardot A, de Leval L, Rosenwald A, Gaulard P, Wulf G, Villate A, Latiere C, Elmaagacli A, Glass B, Poeschel V, Damaj G, Sibon D, Durot E, Bilger K, Banos A, Haenel M, Dreyling M, Keller U, Tiab M, Drenou B, Cornillon J, Nguyen S, Robin M, Nickelsen M, Trumper L, Lenz G, Ziepert M, Schmitz N; French Lymphoma Study Association (LYSA), the Societe Francophone de greffe de moelle et Therapie Cellulaire (SFGM-TC), and the German Lymphoma Alliance (GLA). Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma). J Clin Oncol. 2024 Nov 10;42(32):3788-3794. doi: 10.1200/JCO.24.00554. Epub 2024 Sep 13.","pmid":"39270145","type":"DERIVED"},{"citation":"Schmitz N, Truemper L, Bouabdallah K, Ziepert M, Leclerc M, Cartron G, Jaccard A, Reimer P, Wagner E, Wilhelm M, Sanhes L, Lamy T, de Leval L, Rosenwald A, Roussel M, Kroschinsky F, Lindemann W, Dreger P, Viardot A, Milpied N, Gisselbrecht C, Wulf G, Gyan E, Gaulard P, Bay JO, Glass B, Poeschel V, Damaj G, Sibon D, Delmer A, Bilger K, Banos A, Haenel M, Dreyling M, Metzner B, Keller U, Braulke F, Friedrichs B, Nickelsen M, Altmann B, Tournilhac O. A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. Blood. 2021 May 13;137(19):2646-2656. doi: 10.1182/blood.2020008825.","pmid":"33512419","type":"DERIVED"}],"start_date":{"date":"2009-11"},"study_type":"INTERVENTIONAL","title":"Allo-Allo Tandem Bone Marrow Transplant (BMT)","url":"https://clinicaltrials.gov/study/NCT00984412"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/aatt-nct00984412"}